Markers for hepatitis A, B and C in methadone maintained patients: An unexpectedly high co-infection with silent hepatitis B

Addiction

Volumn 103, Issue 4, 2008, Pages 681-686

  Bart, Gavin ^a   Piccolo, Paola ^b   Zhang, Linqi ^a,c   Jacobson, Ira ^d   Schaefer, Robert A ^d   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c INSTITUTE OF PATHOGEN BIOLOGY   (China)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hepatitis B; Hepatitis C; Methadone maintenance; Occult infection; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHADONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENOTYPE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE;

ADULT; AGED; CARRIER STATE; DNA, VIRAL; FEMALE; HEPATITIS ANTIGENS; HEPATITIS, VIRAL, HUMAN; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; NARCOTICS; NEW YORK CITY; SEROLOGIC TESTS;

EID: 40749144862     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02151.x     Document Type: Article

References (40)

1. Steigmann F., Hyman S., Goldbloom R. Infectious hepatitis (homologous serum type) in drug addicts. Gastroenterology 1950 15 : 642 6.
2. Kreek M. J., Dodes L., Kane S., Knobler J., Martin R. Long-term methadone maintenance therapy: effects on liver function. Ann Intern Med 1972 77 : 598 602.
3. Miller D. J., Kleber H., Bloomer J. R. Chronic hepatitis associated with drug abuse: significance of hepatitis B virus. Yale J Biol Med 1979 52 : 135 40.
4. Novick D. M., Gelb A. M., Stenger R. J., Yancovitz S. R., Adelsberg B., Chateau F. et al. Hepatitis B serologic studies in narcotic users with chronic liver disease. Am J Gastroenterol 1981 75 : 111 15.
5. Selvey L. A., Denton M., Plant A. J. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus. Aust NZ J Public Health 1997 21 : 102 4.
6. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997 92 : 999 1005.
7. Piccolo P., Borg L., Lin A., Melia D., Ho A., Kreek M. J. Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment. J Addict Dis 2002 21 : 55 66.
8. Sylvestre D. L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002 67 : 117 23.
9. Bart G., Borg L., Piccolo P., Wells A., Ho A., Zhang L. et al. Current prevalence of hepatitis A, B, and C and HIV-1 serologic markers in former opiate addicts in methadone maintenance treatment (MMTP). Drug Alcohol Depend 2001 63 : S12.
10. CDC (Centers for Disease Control). Epidemiologic Notes and Reports Hepatitis A Among Drug Abusers. MMWR 1988 37 : 297 300. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00000024.htm (accessed 20 February 2008).
11. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G. et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998 338 : 286 90.
12. Fisher D. G., Reynolds G. L., Jaffe A., Perez M. J. Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County, California. J Addict Dis 2006 25 : 25 32.
13. Reimer J., Lorenzen J., Baetz B., Fischer B., Rehm J., Haasen C. et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007 22 : 80 5.
14. Lok A. S., McMahon B. J. Chronic hepatitis B. Hepatology 2007 45 : 507 39.
15. Grob P., Jilg W., Bornhak H., Gerken G., Gerlich W., Gunther S. et al. Serological pattern 'anti-HBc alone': report on a workshop. J Med Virol 2000 62 : 450 5.
16. Hu K. Q. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002 9 : 243 57.
17. Hoofnagle J. H., Seeff L. B., Bales Z. B., Zimmerman H. J. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978 298 : 1379 83.
18. Saito T., Shinzawa H., Uchida T., Kawamata O., Honma S., Watanabe H. et al. Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B. J Med Virol 1999 58 : 325 31.
19. Sanchez-Quijano A., Jauregui J. I., Leal M., Pineda J. A., Castilla A., Abad M. A. et al. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 1993 17 : 288 93.
20. Jilg W., Sieger E., Zachoval R., Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995 23 : 14 20.
21. Bart G., Piccolo P., Wells A., Ho A., Zhang L., Handy S. et al. Hepatitis C virus and serologically silent hepatitis B virus coinfection in former opiate addicts in methadone-maintenance treatment (MMT). Hepatology 2002 36 : 354A.
22. Sum S. S.-M., Wong D. K.-H., Yuen M. F., Yuan H. J., Yu J., Lai C. L. et al. Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA. J Clin Microbiol 2004 42 : 3438 40.
23. Mommenja-Marin H., Mondou E., Blum M., Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003 37 : 1309 19.
24. Weissenbacher M., Rossi D., Radulich G., Sosa-Estani S., Vila M., Vivas E. et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis 2003 37 : S348 S352.
25. Njoh J., Zimmo S. Prevalence of antibodies to hepatitis C virus in drug-dependent patients in Jeddah, Saudi Arabia. East Afr Med J 1997 74 : 89 91.
26. Luksamijarulkul P., Plucktaweesak S. High hepatitis C seroprevalence in Thai intravenous drug abusers and qualitative risk analysis. Southeast Asian J Trop Med Public Health 1996 27 : 654 8.
27. Goldberg D., Cameron S., McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Commun Dis Public Health 1998 1 : 95 7.
28. Tennant F., Moll D. Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts. J Addict Dis 1995 14 : 35 49.
29. Fingerhood M. I., Jasinski D. R., Sullivan J. T. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 1993 153 : 2025 30.
30. Novick D. M., Ochshorn M., Ghali V., Croxson T. S., Mercer W. D., Chiorazzi N. et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989 250 : 606 10.
31. Brechot C., Thiers V., Kremsdorf D., Nalpas B., Pol S., Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001 34 : 194 203.
32. Chen C. J., Yang H. I., Su J., Jen C. L., You S. L., Lu S. N. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
33. Zignego A. L., Fontana R., Puliti S., Barbagli S., Monti M., Careccia G. et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997 51 : 313 18.
34. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M. E., Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999 341 : 22 6.
35. Fukuda R., Ishimura N., Niigaki M., Hamamoto S., Satoh S., Tanaka S. et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999 58 : 201 7.
36. Sagnelli E., Coppola N., Scolastico C., Mogavero A. R., Filippini P., Piccinino F. HCV genotype and 'silent' HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001 64 : 350 5.
37. Sagnelli E., Coppola N., Scolastico C., Mogavero A. R., Stanzione M., Filippini P. et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J Med Virol 2001 65 : 681 7.
38. Squadrito G., Pollicino T., Cacciola I., Caccamo G., Villari D., La Masa T. et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006 106 : 1326 30.
39. Torbenson M., Kannangai R., Astemborski J., Strathdee S. A., Vlahov D., Thomas D. L. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004 39 : 51 7.
40. Borg L., Khuri E., Wells A., Melia D., Bergasa N. V., Ho A. et al. Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction 1999 94 : 489 93.